Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Michter’s 2025 Legacy Series features two limited releases: Bomberger’s Declaration Kentucky Straight Bourbon (54% ABV) and ...

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

The clinical-stage biopharmaceutical company reported that the trial met its primary endpoint, with up to 59.1% of participants achieving MASH resolution without worsening of fibrosis in an ...

FOX21 Storm Team Meteorologist Robert Hahn took the Storm Squatch on the road to Downtown Colorado Springs to visit with ...

Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage ...

At the heart of Monsters Are Coming is the city. This bastion of civilisation is under siege by swarms of inky black spider-like monsters, but it’s not going to take this assault lying down. No, the ...

FOOTBALL icon David Beckham has been pictured recovering in his hospital bed after a mystery ailment. Posting a heartwarming ...

But despite its setting, the show often emphasized themes of resilience and perseverance. Through varied episodes, M*A*S*H ...